5-Methoxy 2-aminoindane - Clearmind Medicine
Alternative Names: 5-MeO-AI - Clearmind Medicine; CMND-100; MEAI - Clearmind MedicineLatest Information Update: 20 Mar 2026
At a glance
- Originator Clearmind Medicine
- Developer Clearmind Medicine; SciSparc
- Class Amines; Antipsychotics; Drug withdrawal therapies; Ethers; Indans; Obesity therapies
- Mechanism of Action 5-HT1A serotonin receptor modulators; Serotonin 5-HT2A receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Alcoholism
- Preclinical Cocaine-related disorders; Metabolic syndrome; Obesity
Most Recent Events
- 10 Mar 2026 Clearmind Medicine files an International patent application for 5-Methoxy 2-aminoindane combination therapy
- 04 Mar 2026 Updated adverse events data from phase I/IIa trial in Alcoholism released by Clearmind Medicine
- 09 Feb 2026 Updated topline adverse events data from the second cohort of a phase I/IIa trial in Alcoholism released by Clearmind Medicine